Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Andrea Giacomelli, Laura Pezzati & Stefano Rusconi. (2020) The crosstalk between antiretrovirals pharmacology and HIV drug resistance. Expert Review of Clinical Pharmacology 13:7, pages 739-760.
Read now
Read now
Beatriz Larru, Jessica Eby & Elizabeth D Lowenthal. (2014) Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. Pediatric Health, Medicine and Therapeutics 5, pages 29-42.
Read now
Read now
Articles from other publishers (34)
Frank Eric Tatsing Foka & Hazel Tumelo Mufhandu. (2023) Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review. Viruses 15:8, pages 1732.
Crossref
Crossref
Daniela Zizioli, Sara Ferretti, Giorgio Tiecco, Luca Mignani, Eugenio Monti, Francesco Castelli, Eugenia Quiros-Roldan & Isabella Zanella. (2023) Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model. International Journal of Molecular Sciences 24:14, pages 11664.
Crossref
Crossref
Bin Su, Guiju Gao, Min Wang, Yanqiu Lu, Linghua Li, Chen Chen, Yuanyuan Chen, Chuan Song, Fengting Yu, Ying Li, Yixin Liu, Yang Luo, Haolan He, Cong Cheng, Lixia Xu, Tong Zhang, Lijun Sun, An Liu, Wei Xia, Yuanyuan Qin, Qingxia Zhao, Hongxia Wei, Weiping Cai, Yaokai Chen, Fujie Zhang & Hao Wu. (2023) Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. The Lancet Regional Health - Western Pacific 36, pages 100769.
Crossref
Crossref
Divya Vemula, Perka Jayasurya, Varthiya Sushmitha, Yethirajula Naveen Kumar & Vasundhra Bhandari. (2023) CADD, AI and ML in drug discovery: A comprehensive review. European Journal of Pharmaceutical Sciences 181, pages 106324.
Crossref
Crossref
Bárbara Costa & Nuno Vale. (2022) Efavirenz: History, Development and Future. Biomolecules 13:1, pages 88.
Crossref
Crossref
Runji Zhang, Jian Bao, Jialu Qiao, Wenshuang Li, Feng Qian, Kanghong Hu & Binlian Sun. (2021) Long-term efavirenz exposure induced neuroinflammation and cognitive deficits in C57BL/6 mice. Biochemical and Biophysical Research Communications 584, pages 46-52.
Crossref
Crossref
Susana Santos Braga, Firas El-Saleh, Karyna Lysenko & Filipe A. Almeida Paz. (2021) Inclusion Compound of Efavirenz and γ-Cyclodextrin: Solid State Studies and Effect on Solubility. Molecules 26:3, pages 519.
Crossref
Crossref
Deepak Pradhan, Prativa Biswasroy, Amit Goyal, Goutam Ghosh & Goutam Rath. (2021) Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections. AAPS PharmSciTech 22:1.
Crossref
Crossref
Venkata Bharat Nishtala, Chityala Mahesh, G. Bhargavi, Vijay Kumar Pasala & Srinivas Basavoju. (2019) Synthesis of spirooxindolocarbamates based on Betti reaction: antibacterial, antifungal and antioxidant activities. Molecular Diversity 24:4, pages 1139-1147.
Crossref
Crossref
Jukka Hakkola, Janne Hukkanen, Miia Turpeinen & Olavi Pelkonen. (2020) Inhibition and induction of CYP enzymes in humans: an update. Archives of Toxicology 94:11, pages 3671-3722.
Crossref
Crossref
Dhanashree H. Surve, Yugandhara B. Jirwankar, Vikas D. Dighe & Anil B. Jindal. (2020)
Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer–Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and
In Vivo
Biodistribution
. Molecular Pharmaceutics 17:10, pages 3990-4003.
Crossref
Crossref
Mitali Patel, Ruhi Shah & Krutika Sawant. (2020) Recent Advances in Drug Delivery Strategies for Improved Therapeutic Efficacy of Efavirenz. Recent Patents on Nanotechnology 14:2, pages 119-127.
Crossref
Crossref
CH. RAMESH, DHARMASOTH RAMA DEVI DEVI, M.N.B. SRINIVAS, S. RADHA KRISHNA, NAGARAJU RAJANA & K. BASAVAIAH. (2020) Development and Validation of RP-Chiral HPLC Method for
Determination of (R)-Enantiomer Excess Content in Efavirenz. Asian Journal of Chemistry 32:9, pages 2208-2212.
Crossref
Crossref
Ansgar Brüning, Julia Jückstock, Bernd Kost, Panagiotis Tsikouras, Tobias Weissenbacher, Sven Mahner & Ioannis Mylonas. (2017) Induction of DNA damage and apoptosis in human leukemia cells by efavirenz. Oncology Reports 37:1, pages 617-621.
Crossref
Crossref
Mônica M. Bastos, Carolina C.P. Costa, Talitha C. Bezerra, Fernando de C. da Silva & Núbia Boechat. (2016) Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. European Journal of Medicinal Chemistry 108, pages 455-465.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
687
736
.
Marlene Weiß, Bernd Kost, Ingrid Renner-Müller, Eckhard Wolf, Ioannis Mylonas & Ansgar Brüning. (2015) Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Endothelial Cells. Cardiovascular Toxicology 16:1, pages 90-99.
Crossref
Crossref
Abiy Habtewold, Eyasu Makonnen, Wondwossen Amogne, Getnet Yimer, Getachew Aderaye, Leif Bertilsson, Jürgen Burhenne & Eleni Aklillu. (2015) Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics 16:10, pages 1047-1064.
Crossref
Crossref
Arun K. Ghosh & Margherita Brindisi. (2015) Organic Carbamates in Drug Design and Medicinal Chemistry. Journal of Medicinal Chemistry 58:7, pages 2895-2940.
Crossref
Crossref
A Olagunju, O Bolaji, A Amara, L Else, O Okafor, E Adejuyigbe, J Oyigboja, D Back, S Khoo & A Owen. (2015) Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clinical Pharmacology & Therapeutics 97:3, pages 298-306.
Crossref
Crossref
Alessandro Schipani, David Back, Andrew Owen, Gerry Davies, Saye Khoo & Marco Siccardi. (2014) Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. Clinical Pharmacokinetics 54:1, pages 107-116.
Crossref
Crossref
Laurence Borand, Yoann Madec, Didier Laureillard, Monidarin Chou, Olivier Marcy, Phearavin Pheng, Narom Prak, Chindamony Kim, Khemarin Kim Lak, Chanroeun Hak, Bunnet Dim, Eric Nerrienet, Arnaud Fontanet, Thim Sok, Anne E. Goldfeld, François-Xavier Blanc & Anne-Marie Taburet. (2014) Plasma Concentrations, Efficacy and Safety of Efavirenz in HIV-Infected Adults Treated for Tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial). PLoS ONE 9:3, pages e90350.
Crossref
Crossref
Steffen Wildum, Daniela Paulsen, Kai Thede, Helga Ruebsamen-Schaeff & Holger Zimmermann. (2013)
In Vitro
and
In Vivo
Activities of AIC292, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
. Antimicrobial Agents and Chemotherapy 57:11, pages 5320-5329.
Crossref
Crossref
Michael B Gatch, Alexey Kozlenkov, Ren-Qi Huang, Wenjuan Yang, Jacques D Nguyen, Javier González-Maeso, Kenner C Rice, Charles P France, Glenn H Dillon, Michael J Forster & John A Schetz. (2013) The HIV Antiretroviral Drug Efavirenz has LSD-Like Properties. Neuropsychopharmacology 38:12, pages 2373-2384.
Crossref
Crossref
Nicholas A. Meanwell, Stanley V. D'Andrea, Christopher W. Cianci, Ira B. Dicker, Kap‐Sun Yeung, Makonen Belema & Mark Krystal. 2013. Drug Discovery. Drug Discovery
439
515
.
Marco Siccardi, Adeniyi Olagunju, Kay Seden, Farid Ebrahimjee, Steve Rannard, David Back & Andrew Owen. (2013) Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacology 1:1.
Crossref
Crossref
Rodrigo Cristofoletti, Anita Nair, Bertil Abrahamsson, D.W. Groot, Sabine Kopp, Peter Langguth, James E. Polli, Vinod P. Shah & Jennifer B. Dressman. (2013) Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Efavirenz. Journal of Pharmaceutical Sciences 102:2, pages 318-329.
Crossref
Crossref
Iris Usach, Virginia Melis & José-Esteban Peris. (2013) Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. Journal of the International AIDS Society 16:1, pages 18567.
Crossref
Crossref
A. Habtewold, W. Amogne, E. Makonnen, G. Yimer, K.-D. Riedel, N. Ueda, A. Worku, W. E. Haefeli, L. Lindquist, G. Aderaye, J. Burhenne & E. Aklillu. (2011) Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. Journal of Antimicrobial Chemotherapy 66:10, pages 2350-2361.
Crossref
Crossref
Jayakanthan Mannu, Pranitha Jenardhanan & Premendu P. Mathur. (2010) A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs. Journal of Molecular Modeling 17:8, pages 1847-1854.
Crossref
Crossref
Romuald Corbau, Julie Mori, Chris Phillips, Lesley Fishburn, Alex Martin, Charles Mowbray, Wendy Panton, Caroline Smith-Burchnell, Adele Thornberry, Heather Ringrose, Thorsten Knöchel, Steve Irving, Mike Westby, Anthony Wood & Manos Perros. (2010) Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy 54:10, pages 4451-4463.
Crossref
Crossref
Ana Blas-García, Nadezda Apostolova, Daniel Ballesteros, Daniel Monleón, Jose M. Morales, Milagros Rocha, Victor M. Victor & Juan V. Esplugues. (2010) Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52:1, pages 115-125.
Crossref
Crossref
Marie-Pierre de Béthune. (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009). Antiviral Research 85:1, pages 75-90.
Crossref
Crossref
Jeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, Richard B Pollard, Jose Valdez Ramalho Madruga, Daniel S Berger, Jing Zhao, Xia Xu, Angela Williams-Diaz, Anthony J Rodgers, Richard JO Barnard, Michael D Miller, Mark J DiNubile, Bach-Yen Nguyen, Randi Leavitt & Peter Sklar. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. The Lancet 374:9692, pages 796-806.
Crossref
Crossref